الصفحة الرئيسية>>Signaling Pathways>> GPCR/G protein>> Oxytocin Receptors>>LIT-001

LIT-001

رقم الكتالوجGC38922

LIT-001 هو أول ناهض لمستقبلات الأوكسيتوسين غير الببتيدية (OT-R) (EC50 = 55 نانومتر ؛ Ki = 226 نانومتر)

Products are for research use only. Not for human use. We do not sell to patients.

LIT-001 التركيب الكيميائي

Cas No.: 2245072-21-1

الحجم السعر المخزون الكميّة
5mg
176٫00
متوفر
10mg
324٫00
متوفر
25mg
510٫00
متوفر
50mg
881٫00
متوفر
100mg
1344٫00
متوفر
200mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social interaction in a mouse model of autism[1].

In vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only[1].

LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD )[1]. Animal Model: Oprm1-/- mice (bred in house on a 50% 129SVPas-50% C57BL/6J hybrid background)[1]

[1]. Frantz MC, et al. LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. J Med Chem. 2018 Oct 11;61(19):8670-8692.

مراجعات

Review for LIT-001

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LIT-001

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.